# Afrezza With Basal Combination (ABC): Afrezza® Combined With AID Pump or Insulin Degludec in Adults With Type 1 Diabetes

> **NCT05243628** · PHASE4 · COMPLETED · sponsor: **Mannkind Corporation** · enrollment: 33 (actual)

## Conditions studied

- Type 1 Diabetes

## Interventions

- **BIOLOGICAL:** Afrezza (insulin human) Inhalation Powder
- **BIOLOGICAL:** insulin degludec
- **DEVICE:** Continuous Subcutaneous Insulin Infusion (CSII) pump with Automatic Insulin Delivery (AID)

## Key facts

- **NCT ID:** NCT05243628
- **Lead sponsor:** Mannkind Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-31
- **Primary completion:** 2022-10-17
- **Final completion:** 2022-10-17
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2025-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05243628

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05243628, "Afrezza With Basal Combination (ABC): Afrezza® Combined With AID Pump or Insulin Degludec in Adults With Type 1 Diabetes". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05243628. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*